Literature DB >> 28068460

Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder.

Stewart A Shankman1,2, Stephanie M Gorka2, Andrea C Katz2, Daniel N Klein3, John C Markowitz4, Bruce A Arnow5, Rachel Manber5, Barbara O Rothbaum6, Michael E Thase7, Alan F Schatzberg5, Martin B Keller8, Madhukar H Trivedi9, James H Kocsis10.   

Abstract

OBJECTIVE: Side effects to antidepressant medication can affect the efficacy of treatment, but few predictors foretell who experiences side effects and which side effects they experience. This secondary data analysis examined whether depressed patients with comorbid panic disorder were more likely to experience side effects than those without panic disorder. The study also examined whether greater burden of side effects predicted a poorer treatment course for patients with panic disorder than those without panic disorder. To examine the specificity of these effects, analyses also examined 2 other anxiety disorders-social phobia and generalized anxiety disorder (GAD).
METHODS: Between 2002 and 2006, a large sample (N = 808) of chronically depressed individuals (assessed using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders [SCID-IV]) received antidepressants according to a predetermined algorithm for 12 weeks. Every 2 weeks, depressive symptoms (per the Hamilton Depression Rating Scale) and side effects (specific side effects as well as several indicators of side effect burden) were assessed.
RESULTS: Lifetime diagnosis of panic disorder (assessed using the SCID-IV) at baseline was associated with higher likelihood of gastrointestinal (OR = 1.6 [95% CI, 1.0-2.6]), cardiac (OR = 1.8 [95% CI, 1.1-3.1]), neurologic (OR = 2.6 [95% CI, 1.6-4.2]), and genitourinary side effects (OR = 3.0 [95% CI, 1.7-5.3]) during treatment. Increases in side effect frequency, intensity, and impairment over time were more strongly associated with increases in depressive symptoms for patients with panic disorder compared to those without panic disorder. Neither social phobia nor GAD was associated with these effects.
CONCLUSIONS: Potentially due to heighte​ned interoceptive awareness of changes in their body, chronically depressed individuals with panic disorder may be at greater risk than those without panic disorder for antidepressant side effects and to experience a worsening of depressive symptoms as a result of these side effects over time. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00057551​. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28068460     DOI: 10.4088/JCP.15m10370

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.

Authors:  Robert M Anthenelli; Michael Gaffney; Neal L Benowitz; Robert West; Thomas McRae; Cristina Russ; David Lawrence; Lisa St Aubin; Alok Krishen; A Eden Evins
Journal:  J Gen Intern Med       Date:  2019-03-07       Impact factor: 5.128

Review 2.  Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders.

Authors:  Yoo Jin Jung; David Tweedie; Michael T Scerba; Dong Seok Kim; Maria Francesca Palmas; Augusta Pisanu; Anna R Carta; Nigel H Greig
Journal:  Front Neurosci       Date:  2021-03-29       Impact factor: 4.677

3.  Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.

Authors:  Taylor A Braund; Gabriel Tillman; Donna M Palmer; Evian Gordon; A John Rush; Anthony W F Harris
Journal:  Transl Psychiatry       Date:  2021-08-04       Impact factor: 6.222

4.  The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.

Authors:  Ella J Daly; Ibrahim Turkoz; Giacomo Salvadore; Maggie Fedgchin; Dawn F Ionescu; H Lynn Starr; Stephane Borentain; Madhukar H Trivedi; Michael E Thase; Jaskaran B Singh
Journal:  Depress Anxiety       Date:  2021-07-22       Impact factor: 8.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.